Vericel Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Vericel kazanç ve gelirinin sırasıyla yıllık 51.6% ve 22% oranında artması tahmin edilirken, EPS'nin yıllık 51.1% oranında büyümesi bekleniyor.

Anahtar bilgiler

51.6%

Kazanç büyüme oranı

51.1%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.1%
Gelir büyüme oranı	22.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	15 Oct 2024

Gelecekteki son büyüme güncellemeleri

Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Recent updates

What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You

Jul 12

Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year

Apr 26

Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Mar 02

Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%

Feb 02

Vericel Corporation's (NASDAQ:VCEL) Intrinsic Value Is Potentially 19% Below Its Share Price

Aug 09

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:VCEL - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	376	44	N/A	96	7
12/31/2025	300	27	N/A	78	7
12/31/2024	240	5	N/A	56	7
6/30/2024	215	1	-2	43	N/A
3/31/2024	208	0	2	35	N/A
12/31/2023	198	-3	8	35	N/A
9/30/2023	185	-10	11	32	N/A
6/30/2023	178	-13	13	29	N/A
3/31/2023	169	-17	9	22	N/A
12/31/2022	164	-17	10	18	N/A
9/30/2022	159	-18	14	21	N/A
6/30/2022	155	-16	12	21	N/A
3/31/2022	158	-11	14	22	N/A
12/31/2021	156	-7	21	29	N/A
9/30/2021	154	0	22	30	N/A
6/30/2021	152	9	25	31	N/A
3/31/2021	132	4	19	23	N/A
12/31/2020	124	3	15	18	N/A
9/30/2020	118	0	7	9	N/A
6/30/2020	117	0	10	13	N/A
3/31/2020	123	-12	-6	-3	N/A
12/31/2019	118	-10	-10	-7	N/A
9/30/2019	110	-14	-11	-8	N/A
6/30/2019	102	-18	-17	-14	N/A
3/31/2019	95	-3	-3	-1	N/A
12/31/2018	91	-8	-3	0	N/A
9/30/2018	83	-13	-5	-2	N/A
6/30/2018	75	-17	-12	-9	N/A
3/31/2018	73	-15	N/A	-10	N/A
12/31/2017	64	-17	N/A	-13	N/A
9/30/2017	57	-26	N/A	-23	N/A
6/30/2017	54	-29	N/A	-22	N/A
3/31/2017	50	-31	N/A	-22	N/A
12/31/2016	54	-27	N/A	-20	N/A
9/30/2016	53	-26	N/A	-15	N/A
6/30/2016	54	-23	N/A	-11	N/A
3/31/2016	54	-22	N/A	-11	N/A
12/31/2015	51	-23	N/A	-13	N/A
9/30/2015	50	-20	N/A	-16	N/A
6/30/2015	49	-23	N/A	-23	N/A
3/31/2015	40	-25	N/A	-25	N/A
12/31/2014	29	-26	N/A	-25	N/A
9/30/2014	14	-26	N/A	-24	N/A
6/30/2014	4	-21	N/A	-19	N/A
3/31/2014	0	-22	N/A	-18	N/A
12/31/2013	0	-21	N/A	-20	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VCEL 'nin tahmini kazanç büyümesi (yıllık 51.6% ) tasarruf oranının ( 2.5% ) üzerindedir.

Kazançlar ve Piyasa: VCEL şirketinin kazançlarının (yıllık 51.6% ) US pazarından (yıllık 15.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: VCEL şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: VCEL şirketinin gelirinin (yıllık 22% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: VCEL şirketinin gelirinin (yıllık 22% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VCEL 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Vericel Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Vericel Corporation Reaffirms Revenue Guidance for the Year 2024

Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Vericel Corporation Provides Earnings Guidance for the Year 2024

Price target increased by 11% to US$52.07

Vericel Corporation Provides Earnings Guidance for the Fiscal Year 2024

Price target increased by 7.9% to US$46.23

Recent updates

Vericel Corporation to Report Q3, 2024 Results on Nov 07, 2024

Vericel Corporation Announces FDA Approval and Commercial Availability of MACI Arthro

Vericel Corporation Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns

Vericel Corporation Reaffirms Revenue Guidance for the Year 2024

Vericel Corporation Announces Executive Changes

What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You

CEO, President & Director notifies of intention to sell stock

Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

New minor risk - Shareholder dilution

Vericel Corporation Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

CEO, President & Director exercised options to buy US$1.2m worth of stock.

It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year

Vericel Corporation to Report Q1, 2024 Results on May 08, 2024

CEO, President & Director notifies of intention to sell stock

Vericel Corporation, Annual General Meeting, May 01, 2024

CEO, President & Director notifies of intention to sell stock

Senior VP recently sold US$368k worth of stock

Senior VP notifies of intention to sell stock

Price target increased by 11% to US$52.07

Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Full year 2023 earnings: EPS exceeds analyst expectations

Vericel Corporation Provides Earnings Guidance for the Fiscal Year 2024

CEO, President & Director notifies of intention to sell stock

Vericel Corporation to Report Q4, 2023 Results on Feb 29, 2024

Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%

Price target increased by 7.9% to US$46.23

CEO, President & Director notifies of intention to sell stock

Vericel Corporation Provides Earnings Guidance for the Year 2024

Vericel Corporation Provides Earnings Guidance for the Fourth Quarter and Full-Year 2023

Chief Operating Officer exercised options and sold US$492k worth of stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Vericel Corporation Provides Total Net Revenue Guidance for 2023

Vericel Corporation to Report Q3, 2023 Results on Nov 08, 2023

Vericel Corporation Announces U.S. Commercial Availability of NexoBrid (Anacaulase-Bbb) for the Treatment of Severe Thermal Burns in Adults

Consensus estimates of losses per share improve by 15%

Vericel Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Vericel Corporation to Report Q2, 2023 Results on Aug 02, 2023

Price target increased by 7.9% to US$40.75

Consensus EPS estimates fall by 12%, revenue upgraded

Vericel Corporation Raises Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit

Consensus EPS estimates fall by 48%

Chief Operating Officer exercised options and sold US$95k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 7.1% to US$36.67

Vericel Corporation to Report Q4, 2022 Results on Feb 23, 2023

CEO, President & Director exercised options and sold US$100k worth of stock

CEO, President & Director notifies of intention to sell stock

Vericel Corporation Announces Accelerated Launch Timeline for MACI Arthroscopic Program

Vericel Corporation Provides Revenue Guidance for the Full-Year 2022

Vericel Announces Fda Approval of Nexobrid for the Treatment of Severe Thermal Burns in Adults

Price target increased to US$37.00

Price target decreased to US$33.25

Price target decreased to US$38.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Vericel Corporation Provides Earnings Guidance for the Full-Year 2022

Vericel Corporation to Report Q3, 2022 Results on Nov 09, 2022

Vericel Corporation: Stock Has Fallen, But Not Enough To Make This A Buy

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Vericel Corporation Announces Revenue Guidance for the Full Year of 2022

Vericel Q2 2022 Earnings Preview

Vericel Corporation Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America of Patients with Large Posterior Trunk Burns Treated with Epicel

Vericel Corporation to Report Q2, 2022 Results on Aug 03, 2022

Price target decreased to US$45.20

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind